Swiss CDMO Lonza has increased capacity and capabilities at its Visp, Switzerland site, with the completion of a new line for cGMP clinical and commercial drug product manufacturing.
The FDA has issued the ICH final guidance, Q13 Continuous Manufacturing of Drug Substances and Drug Products, and a discussion paper for stakeholder comment.